These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 7964884

  • 1. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
    Kuriyama M, Tokimura Y, Fujiyama J, Utatsu Y, Osame M.
    J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
    [Abstract] [Full Text] [Related]

  • 2. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
    Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S.
    Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
    [Abstract] [Full Text] [Related]

  • 3. High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
    Kuriyama M, Fujiyama J, Kasama T, Osame M.
    J Lipid Res; 1991 Feb; 32(2):223-9. PubMed ID: 2066659
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.
    Ito S, Kuwabara S, Sakakibara R, Oki T, Arai H, Oda S, Hattori T.
    J Neurol Sci; 2003 Dec 15; 216(1):179-82. PubMed ID: 14607320
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
    Clarenbach JJ, Lindenthal B, Dotti MT, Federico A, Kelleher JK, von Bergmann K.
    Metabolism; 2005 Mar 15; 54(3):335-44. PubMed ID: 15736111
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis.
    Salen G, Batta AK, Tint GS, Shefer S.
    Metabolism; 1994 Aug 15; 43(8):1018-22. PubMed ID: 8052141
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
    Verrips A, Wevers RA, Van Engelen BG, Keyser A, Wolthers BG, Barkhof F, Stalenhoef A, De Graaf R, Janssen-Zijlstra F, Van Spreeken A, Gabreëls FJ.
    Metabolism; 1999 Feb 15; 48(2):233-8. PubMed ID: 10024088
    [Abstract] [Full Text] [Related]

  • 12. Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis.
    Mimura Y, Kuriyama M, Tokimura Y, Fujiyama J, Osame M, Takesako K, Tanaka N.
    J Neurol Sci; 1993 Feb 15; 114(2):227-30. PubMed ID: 8445406
    [Abstract] [Full Text] [Related]

  • 13. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
    Dotti MT, Lütjohann D, von Bergmann K, Federico A.
    Neurol Sci; 2004 Oct 15; 25(4):185-91. PubMed ID: 15549503
    [Abstract] [Full Text] [Related]

  • 14. Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy.
    Watts GF, Mitchell WD, Bending JJ, Reshef A, Leitersdorf E.
    QJM; 1996 Jan 15; 89(1):55-63. PubMed ID: 8730343
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
    Mignarri A, Magni A, Del Puppo M, Gallus GN, Björkhem I, Federico A, Dotti MT.
    J Inherit Metab Dis; 2016 Jan 15; 39(1):75-83. PubMed ID: 26153518
    [Abstract] [Full Text] [Related]

  • 16. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations.
    Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH.
    Arch Neurol; 2002 Apr 15; 59(4):527-9. PubMed ID: 11939886
    [Abstract] [Full Text] [Related]

  • 17. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.
    Fiorucci S, Distrutti E.
    Handb Exp Pharmacol; 2019 Apr 15; 256():265-282. PubMed ID: 31267167
    [Abstract] [Full Text] [Related]

  • 18. Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings.
    Peynet J, Laurent A, De Liege P, Lecoz P, Gambert P, Legrand A, Mikol J, Warnet A.
    Neurology; 1991 Mar 15; 41(3):434-6. PubMed ID: 2006015
    [Abstract] [Full Text] [Related]

  • 19. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.
    Salen G, Grundy SM.
    J Clin Invest; 1973 Nov 15; 52(11):2822-35. PubMed ID: 4355999
    [Abstract] [Full Text] [Related]

  • 20. Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.
    de Sain-van der Velden MG, Verrips A, Prinsen BH, de Barse M, Berger R, Visser G.
    J Inherit Metab Dis; 2008 Dec 15; 31 Suppl 2():S387-93. PubMed ID: 18949577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.